, "",

- . (/) 5-10, 1-10, 0,1-0,2 1/ 5-20.

4.7
10% (500)

: . - , Actynomyces spp., Bacillus antracis, Clostridium spp., Corynebacterium spp. . : 1. 1.1 10% (moxicillini 10

4.7
10%, "INVESA",

: , . 0.1, 0.5 1 , 5 25 . - , , ,

4.7
15%, "INVESA",

15% 15% - , b- . 15% (Actinomyces spp., Bacillus antracis., Clostridium spp.,Corynebacterium spp., Erysipelothrix rhusiopathiae, Streptoccocus spp., Staphilococcus spp., Listria monocyto

4.7
150, "-",

150 1. 1. 150 (Amoxycillin 150) – , , ,

4.7
, ..,

1 -150 . , , , . , (.) Amoxoil retard , 1 150

4.7
LC, "Pfizer",

LC LC - . , , , . LC (Ampiclox LC) , . LC 3 ( ) 75

4.7
30%, "",

-, . . – 35- 200 500 (120 .. 1 ), 5 ; 57

4.7
5% -, "BAYER",

5% , (250 ) 5% , . 250 5% : 1 50 . 1 50 (

4.7
IMM LC

IMM LC - . , , , IMM LC (- Norbrook Laboratories Limited/ , ) l. 1. IMM LC (Bayoclav IMM LC). LC .

4.7
IMM LC

IMM LC , ( 3 ) 200 ( ), 55 ( ), 10 , - , .

4.7
10% -, "BAYER",

1 100 . , , , , , , 10% (Bayer) 10% 10% .

4.7
5%, "BAYER",

1-50 . , , , , , , , , ® 5% , . - .

4.7
, "",

- . : - 1,2 , - 720000 - 0,6 . 1 2 , 20 .

4.7
100

- . (, , ) , (,

4.7
100

. : - , - , - , - -

4.7

. : - . : , , , . : , .

4.7
- FP5 L5

, , -3, - – 12 : - ; - .

4.7
RSP, "Intervet",

MDBK, -3 ( SF-4 Reisinger), - ( EV 908), Pasteurella haemolitica ( 1 6), . - ,

4.7